STARPHARMA HOLDINGS LIMITED ADR
WKN: A2QE42 | ISIN: US8555631022 | Ticker-Symbol: PQ6ASiehe auch STARPHARMA HOLDINGS LIMITED
Frankfurt
03.11.25 | 08:17
1,900 Euro
-1,04 % -0,020
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.10. | STARPHARMA HOLDINGS LIMITED: Quarterly Activities/Appendix 4C Cash Flow Report | 1 | ASX | ||
| 22.10. | STARPHARMA HOLDINGS LIMITED: Upfront payment of USD $5.5 million received from Genentech | 11 | ASX | ||
| 21.10. | STARPHARMA HOLDINGS LIMITED: Australian Microcap Investment Conference presentation | - | ASX | ||
| 21.10. | STARPHARMA HOLDINGS LIMITED: Change of Director's Interest Notice - R Thomas | - | ASX | ||
| 13.10. | STARPHARMA HOLDINGS LIMITED: Notice of 2025 Annual General Meeting/Proxy Form | - | ASX | ||
| 06.10. | STARPHARMA HOLDINGS LIMITED: Change of Director's Interest Notice - C Maley | 2 | ASX | ||
| 06.10. | STARPHARMA HOLDINGS LIMITED: Notification of cessation of securities - SPL | 2 | ASX | ||
| 30.09. | Starpharma and Radiopharm Theranostics Partner to Develop Novel Radiotherapy Asset | 4 | smallcaps.com.au | ||
| STARPHARMA HOLDINGS LIMITED ADR Aktie jetzt für 0€ handeln | |||||
| 30.09. | Starpharma and Radiopharm Theranostics Partner on Novel Radiotherapy Asset | 1 | Finance News Network | ||
| 30.09. | STARPHARMA HOLDINGS LIMITED: RAD: Radiopharm Theranostics Partners with SPL on Research | - | ASX | ||
| 30.09. | STARPHARMA HOLDINGS LIMITED: Research and Option Agreement with Radiopharm Theranostics | - | ASX | ||
| 22.09. | Starpharma Announces a Collaboration and License Agreement with Genentech | 191 | GlobeNewswire (Europe) | MELBOURNE, Australia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Starpharma (ASX: SPL, US OTC: SPHRY), an innovative Australian biotechnology company, today announced the signing of a collaboration and license... ► Artikel lesen | |
| 22.09. | Health Check: Starpharma revs up on Big Pharma deal worth up to $855m | 4 | Stockhead | ||
| 22.09. | Lunch Wrap: Newmont jumps on $900m asset sale, Starpharma soars | 29 | Stockhead | ||
| 22.09. | Starpharma Partners with Genentech to Develop Innovative Cancer Therapies Using DEP Technology | 11 | smallcaps.com.au | ||
| 22.09. | Top 10 at 11: ASX starts week on the up as Starpharma shines on Big Pharma deal | 1 | Stockhead | ||
| 22.09. | Starpharma Inks Major Deal with Genentech | 7 | Finance News Network | ||
| 22.09. | STARPHARMA HOLDINGS LIMITED: Presentation to Accompany License Agreement with Genentech | 1 | ASX | ||
| 22.09. | STARPHARMA HOLDINGS LIMITED: Starpharma Announces License Agreement with Genentech | - | ASX | ||
| 17.09. | STARPHARMA HOLDINGS LIMITED: Date of Annual General Meeting 2025 | - | ASX |
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| AVIDITY BIOSCIENCES | 69,80 | +0,17 % | Novartis will US-Biotech Avidity Biosciences für 12 Mrd USD übernehmen | DJ Novartis will US-Biotech Avidity Biosciences für 12 Mrd USD übernehmen
Von Dylan Tokar und Peter Loftus
DOW JONES--Novartis will den US-Biotech-Konzern Avidity Biosciences für 12 Milliarden... ► Artikel lesen | |
| CABALETTA BIO | 3,625 | 0,00 % | Cabaletta Bio Reports Positive Rese-cel Data Across Myositis, SSc, and SLE Trials | ||
| RECURSION PHARMACEUTICALS | 5,500 | 0,00 % | Could Recursion Pharmaceuticals Be the Next Big Artificial Intelligence (AI) Stock? | ||
| VENTYX BIOSCIENCES | 8,560 | 0,00 % | Morning Market Movers: Ventyx Biosciences, Brera Holdings, Safe & Green Holdings, American Rebel Holdings See Big Swings | CANBERA (dpa-AFX) - At 8:05 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| RANI THERAPEUTICS | 2,185 | 0,00 % | Rani Therapeutics schließt Privatplatzierung ab und besetzt Vorstand neu | ||
| DYNE THERAPEUTICS | 22,580 | -4,08 % | Why Dyne Therapeutics Stock Crushed the Market on Monday | ||
| BEAM THERAPEUTICS | 24,995 | +5,09 % | Beam Therapeutics Announces U.S. FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to BEAM-101 for the Treatment of Sickle Cell Disease | CAMBRIDGE, Mass., Aug. 14, 2025 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that... ► Artikel lesen | |
| IMMUNOVANT | 24,700 | -0,44 % | Immunovant gains amid takeover speculation | ||
| ARCUTIS BIOTHERAPEUTICS | 25,320 | +1,61 % | Arcutis Biotherapeutics, Inc.: Arcutis Outlines Strategy for Driving Sustainable Growth and Announces Third Quarter 2025 Financial Results | Q3 2025 net product revenue for ZORYVE® (roflumilast) was $99.2 million, a 122% increase compared to Q3 of 2024, and a 22% increase compared to Q2 of 2025 ZORYVE cream 0.05% received U.S. Food and... ► Artikel lesen | |
| INHIBRX BIOSCIENCES | 81,40 | +3,75 % | Morning Market Movers: Picard Medical, Qualigen Therapeutics, Inhibrx Biosciences, MidWestOne Financial GroupSee Big Swings | BEIJING (dpa-AFX) - At 7:45 a.m. ET on Friday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 18,900 | +1,45 % | Summit Therapeutics: Daten überzeugen - BioNTech beobachten! | Am morgigen Dienstag neigt sich die Jahrestagung der European Society for Medical Oncology (ESMO) in Berlin schon wieder dem Ende entgegen. Zahlreiche Unternehmen haben bereits am Wochenende frische... ► Artikel lesen | |
| STRUCTURE THERAPEUTICS | 33,320 | +3,25 % | Structure Therapeutics stock rating reiterated at Piper Sandler ahead of key data | ||
| PRIME MEDICINE | 4,950 | +13,79 % | Prime Medicine, Inc.: Prime Medicine to Host Virtual KOL Event to Showcase Wilson's Disease Strategy | ||
| ARCUS BIOSCIENCES | 19,645 | -2,41 % | Arcus Biosciences stock falls after pricing $250 million public offering | ||
| MINERALYS THERAPEUTICS | 40,830 | -0,73 % | Mineralys Therapeutics, Inc.: Mineralys Therapeutics Announces Late-Breaking Presentation of Data from the Launch-HTN Pivotal Trial of Lorundrostat in Uncontrolled or Resistant Hypertension at 34th European Meeting on Hypertension ... | - Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world... ► Artikel lesen |
STARPHARMA HOLDINGS LIMITED ADR gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -1,04 % bei einem Aktienkurs von 1,900 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu STARPHARMA HOLDINGS LIMITED ADR finden Sie auf Wallstreet Online.